AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16719027 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic strapping
Number of subjects: 33
Study 16719027 — intervention group
Group type: COMPARATOR
Intervention: Placebo strapping
Number of subjects: 33
Study 16719027 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 33
Study 16719027 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of movement and function
Number of subjects: 33
Study 15837997 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐275291, 1,200 mg orally daily
Number of subjects: 774
Study 15837997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 774
Study 12222541 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartford Hospital nomogram
Number of subjects: 90
Study 12222541 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnes‐Jewish Hospital nomogram
Number of subjects: 90
Study 12222541 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Rochester nomogram
Number of subjects: 90
Study 12222541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanford Guide nomogram
Number of subjects: 90
Study 10483132 — intervention group
Group type: EXPERIMENTAL
Intervention: General population and medical practitioners
Number of subjects: 14063
Study 10483132 — intervention group
Group type: EXPERIMENTAL
Intervention: General population
Number of subjects: 14063
Study 10483132 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical practitioners
Number of subjects: 14063
Study 10483132 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors
Number of subjects: 14063
Study 10483132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 14063
Study 7605852 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg b.d. for 4 weeks
Number of subjects: 52
Study 7605852 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg b.d. for 4 weeks
Number of subjects: 52
Study 7605852 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.d. for 4 weeks
Number of subjects: 52
Study 7605852 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (1 week)
Number of subjects: 52
Study 7605852 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (1 week)
Number of subjects: 52
Study 2193640 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40
Study 378040 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg t.i.d.
Number of subjects: 32
Study 378040 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 1.25 mg t.i.d.
Number of subjects: 32
Study 378040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30565155 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg enteric-coated aspirin once daily
Number of subjects: 7971
Study 28207724 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Prescription plus Kia Ākina (KA/GRx)
Number of subjects: 108
Study 28207724 — intervention group
Group type: COMPARATOR
Intervention: Green Prescription alone (GRx)
Number of subjects: 108
Study 25919061 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg bid
Number of subjects: 5000
Study 25919061 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with standard care)
Number of subjects: 5000
Study 23599013 — intervention group
Group type: EXPERIMENTAL
Intervention: Shang Ring (SR)
Number of subjects: 138
Study 23599013 — intervention group
Group type: COMPARATOR
Intervention: Forceps-guided AMC
Number of subjects: 138
Study 21852629 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (standard care plus 12 months of telephone counseling and tailored newsletters)
Number of subjects: 266
Study 21852629 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 266
Study 21852629 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 266
Study 19320574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 minutes of surgical hand antisepsis with alcohol-based hand rub (45% vol/vol 2-propanol, 30% vol/vol 1-propanol, and 0.2% mecetronium ethylsulphate)
Number of subjects: 32
Study 19320574 — intervention group
Group type: COMPARATOR
Intervention: 3 minutes of surgical hand antisepsis with alcohol-based hand rub (45% vol/vol 2-propanol, 30% vol/vol 1-propanol, and 0.2% mecetronium ethylsulphate)
Number of subjects: 32
Study 19320574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 minutes of surgical hand antisepsis with alcohol-based hand rub
Number of subjects: 32
Study 19320574 — intervention group
Group type: COMPARATOR
Intervention: 3 minutes of surgical hand antisepsis with alcohol-based hand rub
Number of subjects: 32
Study 17650781 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy expectations and outcome expectations related to exercise
Number of subjects: 389
Study 17650781 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy expectations
Number of subjects: 389
Study 17650781 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and mental status or depressive symptoms
Number of subjects: 389
Study 17650781 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, cognitive status, physical and mental health status, pain, fear, outcome expectations, and depressive symptoms
Number of subjects: 389
Study 14739148 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) 3 mg/kg/day every 21 days
Number of subjects: 17
Study 14739148 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 17
Study 11465701 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/day)
Number of subjects: 434
Study 11465701 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (2.5 mg/week)
Number of subjects: 434
Study 11465701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 11465701 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/day) and Folinic acid (2.5 mg/week)
Number of subjects: 434
Study 9930426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hancock valves (group A)
Number of subjects: 77
Study 9930426 — intervention group
Group type: COMPARATOR
Intervention: Stentless bioprostheses (group B)
Number of subjects: 77
Study 8067370 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral support
Number of subjects: 13
Study 8067370 — intervention group
Group type: COMPARATOR
Intervention: No oral support
Number of subjects: 13
Study 2904462 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 50
Study 2904462 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime plus metronidazole
Number of subjects: 50
Study 31444908 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM‐C with NBCM (test group 1)
Number of subjects: 3
Study 31444908 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM‐C only (test group 2)
Number of subjects: 3
Study 31444908 — intervention group
Group type: COMPARATOR
Intervention: Natural healing (control group)
Number of subjects: 3
Study 30443174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation with volume guarantee (PCV with VG)
Number of subjects: 80
Study 30443174 — intervention group
Group type: COMPARATOR
Intervention: 1:1 equal ratio ventilation (ERV)
Number of subjects: 80
Study 30443174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PCV with VG and ERV)
Number of subjects: 80
Study 27187451 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein supplementation (WP, n = 15)
Number of subjects: 30
Study 27187451 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Protein sources (FP, n = 15)
Number of subjects: 30
Study 27187451 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein supplementation (WP, n = 9)
Number of subjects: 30
Study 27187451 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Protein sources (FP, n = 12)
Number of subjects: 30
Study 25335089 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time force feedback
Number of subjects: 72
Study 25335089 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocessing force feedback
Number of subjects: 72
Study 25335089 — intervention group
Group type: COMPARATOR
Intervention: No force feedback (control)
Number of subjects: 72
Study 22234322 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Number of subjects: 21
Study 22234322 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 21
Study 20184572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (group A)
Number of subjects: 75
Study 20184572 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (group B)
Number of subjects: 75
Study 20184572 — intervention group
Group type: COMPARATOR
Intervention: L-carnitine (group C)
Number of subjects: 75
Study 20184572 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group D)
Number of subjects: 75
Study 17277732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with paranoid schizophrenia
Number of subjects: 105
Study 17277732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unipolar depression
Number of subjects: 105
Study 17277732 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 105
Study 16238703 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study 16238703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14507127 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic cavity preparation (KCP)
Number of subjects: 0
Study 14507127 — intervention group
Group type: COMPARATOR
Intervention: Rotating instruments
Number of subjects: 0
Study 10090440 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamines (fexofenadine or loratadine) for 2 weeks after 1 week of placebo
Number of subjects: 569
Study 10090440 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 569
Study 8525693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination with inactivated uropathogenic bacteria (Solco‐Urovac)
Number of subjects: 10
Study 8525693 — intervention group
Group type: COMPARATOR
Intervention: Non-immunized control group (age-matched girls with UTI)
Number of subjects: 10
Study 2180234 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules
Number of subjects: 82543
Study 2180234 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of Ty21a Salmonella typhi vaccine in enteric-coated capsules
Number of subjects: 82543
Study 2180234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82543
Study 2180234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a Salmonella typhi vaccine (both doses)
Number of subjects: 82543
Study 548940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefaclor orally
Number of subjects: 25
Study 548940 — intervention group
Group type: COMPARATOR
Intervention: 1 g cephalexin orally
Number of subjects: 25
Study 548940 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g cefaclor orally 4 times daily
Number of subjects: 25
Study 548940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefaclor (single dose)
Number of subjects: 25
Study 31637815 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenogroup 1 (higher burden of co-morbidities, natriuretic peptides, and abnormalities in left ventricular structure and function)
Number of subjects: 1767
Study 31637815 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenogroup 2 (lower prevalence of cardiovascular and non-cardiac co-morbidities but higher burden of diastolic dysfunction)
Number of subjects: 1767
Study 31637815 — intervention group
Group type: COMPARATOR
Intervention: Phenogroup 3 (lower natriuretic peptide levels, intermediate co-morbidity burden, and most favorable diastolic function profile)
Number of subjects: 1767
Study 31427862 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training at maximal fat oxidation intensity (FATmax), 3 days/week for 1 hour/day for 12 weeks
Number of subjects: 30
Study 31427862 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training at maximal fat oxidation intensity (FATmax)
Number of subjects: 30
Study 31427862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 28981875 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10-Hz applied to the left dorsolateral prefrontal cortex, 5 days per week for 21 days)
Number of subjects: 92
Study 28981875 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (10-Hz applied to the left dorsolateral prefrontal cortex, 5 days per week for 21 days)
Number of subjects: 92
Study 28981875 — intervention group
Group type: COMPARATOR
Intervention: Active rTMS predictor in sham-treated patients
Number of subjects: 92
Study 27724923 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily probiotics (four capsules of Vivomixx®; total of 450 billion CFU/day)
Number of subjects: 50
Study 27724923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24526141 — intervention group
Group type: EXPERIMENTAL
Intervention: NCE 4D MRA with STAR spin labeling and variable flip angle sampling
Number of subjects: 9
Study 23964444 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (diclofenac) 75 mg/d with curcumin 1,000 mg/d for 3 months
Number of subjects: 88
Study 23964444 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (diclofenac) 75 mg/d with placebo
Number of subjects: 88
Study 20185666 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HTS)
Number of subjects: 238
Study 20185666 — intervention group
Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 238
Study 17657838 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy of lafutidine, clarithromycin, and amoxicillin
Number of subjects: 40
Study 17657838 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy of lansoprazole, clarithromycin, and amoxicillin
Number of subjects: 40
Study 15662503 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 20
Study 11792748 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing at 1.0 pg/mL threshold for ASCUS
Number of subjects: 3046
Study 11792748 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat cytopathology for ASCUS in women aged 29 years or older
Number of subjects: 3046
Study 11792748 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing at 10.0 pg/mL threshold for ASCUS
Number of subjects: 3046
Study 11792748 — intervention group
Group type: EXPERIMENTAL
Intervention: Any strategy achieving 90% sensitivity for LSIL
Number of subjects: 3046
Study 10964827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpenetrating deep sclerectomy
Number of subjects: 39
Study 10964827 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 39
Study 8629604 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 21
Study 8629604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1479390 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-free condition
Number of subjects: 7
Study 1479390 — intervention group
Group type: COMPARATOR
Intervention: Head-fixed condition
Number of subjects: 7
Study 1479390 — intervention group
Group type: EXPERIMENTAL
Intervention: Active head movements in darkness (labyrinthine-deficient patients)
Number of subjects: 7
Study 1479390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar degeneration and vestibular failure
Number of subjects: 7
Study 6531969 — intervention group
Group type: EXPERIMENTAL
Intervention: RA 27/3 strain rubella vaccine (Rudivax)
Number of subjects: 326
Study 30520252 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW
Number of subjects: 467
Study 30520252 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine (IG)
Number of subjects: 467
Study 30288156 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablet (gemigliptin/metformin SR 50/1,000 mg)
Number of subjects: 24
Study 30288156 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of individual tablets (gemigliptin 50 mg and metformin XR 1,000 mg)
Number of subjects: 24
Study 27650124 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 polyunsaturated fatty acids (PUFAs) treatment for 12 weeks
Number of subjects: 39
Study 27650124 — intervention group
Group type: COMPARATOR
Intervention: ARMS subjects who transitioned to psychotic disorder
Number of subjects: 39
Study 27650124 — intervention group
Group type: COMPARATOR
Intervention: ARMS subjects who did not transition to psychotic disorder
Number of subjects: 39
Study 25379431 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) administration
Number of subjects: 16
Study 25379431 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 16
Study 22950641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E‐coated membrane (VEM) dialyzer
Number of subjects: 10
Study 22950641 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (10 mg daily)
Number of subjects: 10
Study 20088695 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week treatment
Number of subjects: 303
Study 20088695 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week treatment
Number of subjects: 303
Study 20088695 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal drug concentrations
Number of subjects: 303
Study 18852484 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of Ascorbic Acid (AA)
Number of subjects: 9
Study 18852484 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of iron carbonyl
Number of subjects: 9
Study 18852484 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of Ascorbic Acid (AA) plus 150 mg of iron carbonyl
Number of subjects: 9
Study 18852484 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 9
Study 15733070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucose-insulin-potassium (GIK) treatment for 24 hours
Number of subjects: 74
Study 15733070 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 74
Study 15733070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucose-insulin-potassium (GIK) treatment
Number of subjects: 74
Study 12538178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 40
Study 12538178 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 40
Study 12538178 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dextran 70 (DEX)
Number of subjects: 40
Study 12538178 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hetastarch (HES)
Number of subjects: 40
Study 10664047 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost, 0.005% once daily
Number of subjects: 183
Study 10664047 — intervention group
Group type: COMPARATOR
Intervention: Combination of timolol, 0.5% twice daily, and dorzolamide, 2% twice daily
Number of subjects: 183
Study 8703857 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperoxia
Number of subjects: 12
Study 8703857 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study 1539069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (0, 325, 650, 1300 or 1950 mg)
Number of subjects: 6
Study 1539069 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (total dose = 0.625 g/kg; five divided doses)
Number of subjects: 6
Study 28139153 — intervention group
Group type: EXPERIMENTAL
Intervention: Test pudding (12.9g WP and 6g PX)
Number of subjects: 25
Study 28139153 — intervention group
Group type: COMPARATOR
Intervention: Control pudding
Number of subjects: 25
Study 24842476 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg and methotrexate (J-RAPID trial)
Number of subjects: 198
Study 24842476 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg alone or with disease-modifying agents other than methotrexate (HIKARI trial)
Number of subjects: 198
Study 24842476 — intervention group
Group type: COMPARATOR
Intervention: DAS28(ESR) response < 1.2 at week 12
Number of subjects: 198
Study 23044532 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled deep brain stimulation (DBS)
Number of subjects: 5
Study 23044532 — intervention group
Group type: COMPARATOR
Intervention: Acute scheduled vs acute continuous vs off DBS
Number of subjects: 5
Study 21136109 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LPS)
Number of subjects: 40
Study 21136109 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study 19509031 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based environmental management approach combined with routine Aedes control programme
Number of subjects: 64000
Study 19509031 — intervention group
Group type: COMPARATOR
Intervention: Routine Aedes control programme (entomological surveillance, source reduction, selective adulticiding, and health education)
Number of subjects: 64000
Study 17517832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b monotherapy
Number of subjects: 48
Study 17517832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b plus lamivudine combination therapy
Number of subjects: 48
Study 15213566 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART‐MMF group (n = 9)
Number of subjects: 17
Study 15213566 — intervention group
Group type: COMPARATOR
Intervention: HAART group (n = 6)
Number of subjects: 17
Study 15213566 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition group (n = 6)
Number of subjects: 17
Study 15213566 — intervention group
Group type: COMPARATOR
Intervention: No inhibition group (n = 9)
Number of subjects: 17
Study 15213566 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART‐MMF group
Number of subjects: 17
Study 11481357 — intervention group
Group type: EXPERIMENTAL
Intervention: ADocT (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 with tamoxifen)
Number of subjects: 250
Study 11481357 — intervention group
Group type: COMPARATOR
Intervention: ADoc (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 without tamoxifen)
Number of subjects: 250
Study 11481357 — intervention group
Group type: EXPERIMENTAL
Intervention: ADocT
Number of subjects: 250
Study 11481357 — intervention group
Group type: COMPARATOR
Intervention: ADoc
Number of subjects: 250
Study 9707742 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg in children or 500 mg/day in adults for 3 days)
Number of subjects: 145